Guest Editors: George A. Calin1, Silvia Di Agostino2, Sara Donzelli3
1- MD Anderson Cancer Center, Houston, Texas, USA
2- Magna Græcia University, Catanzaro, Italy
3- Regina Elena National Cancer Institute, Rome, Italy
Submission window: January 1st 2022 – December 31st 2022. Submit your research here.
In the last twenty years, thanks to the enormous development of technology and sequencing techniques, many advances have been made in the treatment of cancer, mainly aimed at precision therapies. However, many types of tumors are incurable when diagnosed late, are resistant to the usual therapies and are still lacking in precision therapies. Primary tumors that manage to be cured are often destined for future recurrence and metastasis. In light of these considerations, new biomarkers are still needed for diagnosis, tumor characterization and new targets for cancer treatments. Among the most promising biomarkers and potential targets against cancer, non-coding RNA (ncRNA) are the most likely to have rapid translational application. Their characteristics of high stability and secretion in human fluids make them robust biomarkers.
MicroRNAs (miRNAs) are undoubtedly the most studied of ncRNAs and indeed there are already active clinical trials of miRNAs as therapeutic targets. However, long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) are likewise promising; thus, are molecules to be investigated and validated as biomarkers.
Keywords: LncRNAs, CircRNAs, Biomarkers, Tumorigenesis, Metastasis, Invasion, Epithelial-to-mesenchymal transition (EMT), Drug resistance, Therapy, Therapeutic target, Liquid biopsy.
In this Special Issue of Journal of Experimental & Clinical Cancer Research, we would like to give space to studies that highlight lncRNAs and circRNAs as possible markers of prognosis, diagnosis, drug resistance and metastasis processes in solid and hematopoietic tumors, including studies that develop new molecular, statistical and computational tools for their identification, without forgetting their functional characterization in the various aspects of oncological activities.
Note: As a pre-acceptance check, the journal reserves the right to ask the authors to provide the editors with any raw data and ethics approval documents.